CD274 and rectal cancer: Currently, the clinical trials cooperative group, National Surgical Adjuvant Breast and Bowel Project (NSABP), has completed a phase II trial (FR-2) assessing the activity of PD-L1 inhibition with durvalumab (MEDI4736) following cCRT and prior to surgery in patients with Stage II-IV microsatellite stable rectal cancer and results are awaited.